Floatz logo

Pomalidomide

Hematologic Disorder

Explore 32 assets in Hematologic Disorder →
Floatz Rating
B60/100
Confidence
Indicative
v0.2
Sponsor
Hellenic Society of Hematology
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05581875CT.gov
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
—Not Yet Recruiting———
NCT05298683CT.gov
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
—Unknown———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Hematologic Disorder

AssetSponsorPhaseRating
Pomalidomide (this asset)Hellenic Society of HematologyP2B · 60
CyclophosphamideBaptist Health South FloridaP2/3BBB
FludarabineBaptist Health South FloridaP2BB
Autologous Cd34+ Cells Isolated From Mobilised Peripheral Blood By Positive Selection, Modified By Crispr/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats/Crispr-Associated Protein 9) Mediated Gene Editing Consisting Of A Guide Rna (Grna) Introduced Transiently As Ribonucleoprotein (Rnp) Complex, Targeting The Erythroid Lineage-Specific Enhancer Region Of Bcl11A (B-Cell Lymphoma/Leukemia 11A). The Site-Specific Cleavage By Cas9 Forms A Double Strand Break (Dsb), Which Is Subsequently Repaired By Nonhomologous End-Joining (Nhej), Leading To The Transcriptional Repression Of Bcl11A, A Repressor Of ?-Globin Gene TranscriptionVertex Pharmaceuticals IncorporatedP3BB
KogenateBayerP4BB
BusulfanumBaptist Health South FloridaP2BB
LenalidomideHellenic Society of HematologyP3BB
HydroxyureaSt. Jude Children's Research HospitalP3BB
DexasoneHellenic Society of HematologyP2BB

+42 more in the Hematologic Disorder cohort

Other indications for Pomalidomide

IndicationSponsorPhaseRating
Plasma Cell Myeloma—P4BB · 69
Myelodysplastic Syndrome—P2B · 63
Primary Central Nervous System Lymphoma—P2B · 60

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Pomalidomide in Hematologic Disorder. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/pomalidomide-hematologic-disorder

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →